TCGA-CF-A8HY-01A-11R-A36F-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 11.33377135
- os_event
- false
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.390
- PANCREAS_BETA_CELLS+0.370
- COAGULATION+0.280
- HYPOXIA+0.270
- MYC_TARGETS_V2+0.270
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.240
- P53_PATHWAY+0.200
- KRAS_SIGNALING_DN+0.190
- CHOLESTEROL_HOMEOSTASIS+0.170
- GLYCOLYSIS+0.170
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.450
- INTERFERON_GAMMA_RESPONSE-0.450
- PROTEIN_SECRETION-0.420
- UV_RESPONSE_DN-0.420
- MITOTIC_SPINDLE-0.410
- G2M_CHECKPOINT-0.370
- E2F_TARGETS-0.320
- INFLAMMATORY_RESPONSE-0.320
- ALLOGRAFT_REJECTION-0.260
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.250
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG1265 | — | — | 0.852 |
| 2 | TCGA-UF-A7JF-01A-11R-A34R-07 | — | — | 0.815 |
| 3 | TCGA-CF-A5UA-01A-11R-A28M-07 | — | — | 0.809 |
| 4 | TCGA-GU-A767-01A-11R-A32O-07 | — | — | 0.797 |
| 5 | 0ffd0bed-35a4-4fec-9d56-1d4ae5dcb507 | — | — | 0.795 |
| 6 | TCGA-LL-A5YM-01A-11R-A28M-07 | — | B | 0.788 |
| 7 | R20 | — | — | 0.779 |
| 8 | TCGA-V7-A7HQ-01A-11R-A33J-07 | — | B | 0.777 |
| 9 | 85d43afd-9aac-48ca-a9c4-00357b7207e1 | — | — | 0.774 |
| 10 | SRR9879286 | — | cohortSQ2 | 0.766 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 23 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.390 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.370 | Cobimetinib | — uncovered |
| COAGULATION | 0.280 | Binimetinib | — uncovered |
| HYPOXIA | 0.270 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.270 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.240 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.200 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.190 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.170 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.170 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.150 | Inavolisib | — uncovered |
| MYOGENESIS | 0.140 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.130 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.100 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.100 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.080 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.080 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.060 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.060 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.060 | Inavolisib | — uncovered |